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STATE-OF-THE-ART PAPERS STATE-OF-THE-ART PAPERSAtrial Remodeling and Atrial Fibrillation 2335Stanley Nattel, Masahide Harada
Atrial ﬁbrillation (AF), a major cause of cardiovascular morbidity and mortality, is the
ﬁnal common endpoint of atrial remodeling and is caused by a variety of cardiac diseases
and conditions. In this paper, the authors provide a detailed review on atrial remodeling,
including its mechanism and its role in the AF disease process.STATE-OF-THE-ART PAPERSMyocardial Bridging 2346
Michel T. Corban, Olivia Y. Hung, Parham Eshtehardi, Emad Rasoul-Arzrumly, Michael McDaniel,
Girum Mekonnen, Lucas H. Timmins, Jerre Lutz, Robert A. Guyton, Habib Samady
Patients with myocardial bridging, although often asymptomatic, may present with a variety
of cardiac symptoms including acute coronary syndromes and sudden cardiac death. In this
state-of-the-art paper, the authors review the pathophysiology of myocardial bridging.
Diagnostic modalities and therapeutic options available for managing this anomaly are
also discussed.(continued on page A-33)
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Gonzalo Pizarro, Leticia Fernández-Friera, Valentin Fuster, Rodrigo Fernández-Jiménez,
José M. García-Ruiz, Ana García-Álvarez, Alonso Mateos, María V. Barreiro, Noemí Escalera,
Maite D. Rodriguez, Antonio de Miguel, Inés García-Lunar, Juan J. Parra-Fuertes,
Javier Sánchez-González, Luis Pardillos, Beatriz Nieto, Adriana Jiménez, Raquel Abejón,
Teresa Bastante, Vicente Martínez de Vega, José A. Cabrera, Beatriz López-Melgar, Gabriela Guzman,
Jaime García-Prieto, Jesús G. Mirelis, José Luis Zamorano, Agustín Albarrán, Javier Goicolea,
Javier Escaned, Stuart Pocock, Andrés Iñiguez, Antonio Fernández-Ortiz, Vicente Sánchez-Brunete,
Carlos Macaya, Borja Ibanez
The objective of the METOCARD-CNIC (Effect of Metoprolol in Cardioprotection
During an Acute Myocardial Infarction) trial was to evaluate the long-term effects of
intravenous (IV) metoprolol administration before reperfusion on left ventricular (LV)
function and clinical events. A total of 270 patients with Killip class II anterior ST-segment
elevation myocardial infarction (STEMI) were randomized to either pre-reperfusion IV
metoprolol or a control. In patients with anterior Killip class II STEMI undergoing
primary percutaneous coronary intervention, early IV metoprolol before reperfusion resulted
in higher long-term LVEF, a reduced incidence of severe LV systolic dysfunction and
implantable cardioverter-deﬁbrillator indications, and fewer admissions due to heart failure.
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Gilles Lambert, Francine Petrides, Mathias Chatelais, Dirk J. Blom, Benjamin Choque, Fatiha Tabet,
Gida Wong, Kerry-Anne Rye, Amanda J. Hooper, John R. Burnett, Philip J. Barter, A. David Marais
The objective of this study was to assess whether elevated PCSK9 levels constitute a greater
risk for individuals with heterozygous familial hypercholesterolemia (HeFH) and already
reduced low-density lipoprotein receptor (LDLR) levels. Circulating PCSK9 was measured
in nontreated HeFH patients carrying LDLR missense mutations and in normolipidemic
control subjects. PCSK9 dose-dependently reduced LDLR expression in control and familial
hypercholesterolemia (FH) ﬁbroblasts as well as reduced LDLR abundance in lymphocytes
to similar extents. The results reveal that elevated PCSK9 levels are equally detrimental for
HeFH and non-FH patients, and also explain why both types of patients respond to
monoclonal antibodies targeting PCSK9.
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Leif Friberg
The aim of this study was to examine mortality and liver disease among patients exposed to
dronedarone. A total of 4,856 patients with a diagnosis of atrial ﬁbrillation (AF) who had
received dronedarone and 170,139 patients with AF, but without dronedarone exposure,
were followed for a mean of 1.6 years (Swedish patient registry). After propensity score
matching and adjustment for cofactors, dronedarone patients had lower mortality than other
AF patients (hazard ratio 0.41). There were also no sudden cardiac deaths and no deaths
related to liver failure among patients on dronedarone treatment. Dronedarone, as prescribed
to AF patients in Sweden, has not resulted in an increased risk of death or liver disease.
Editorial Comment: Stefan H. Hohnloser, p. 2385HEART RHYTHM DISORDERSAppropriateness of ICD Generator Replacement 2388Vinay Kini, Mohamad Khaled Souﬁ, Rajat Deo, Andrew E. Epstein, Rupa Bala, Michael Riley,
Peter W. Groeneveld, Alaa Shalaby, Sanjay Dixit
The authors of this study sought to determine how often patients with primary prevention
implantable cardioverter-deﬁbrillators (ICDs) continued to meet guideline-derived
indications at the time of generator change. A left ventricular ejection fraction <35% or
receipt of appropriate device therapy at time of generator replacement were considered
indications for continued ICD therapy. In a cohort of 231 patients, 59 subjects (26%) no
longer met guideline-driven indications for an ICD at the time of generator replacement.
Patients without ICD indications subsequently received appropriate ICD therapies at a
signiﬁcantly lower rate than patients who did (2.8% vs. 10.7% annually). The authors
conclude that approximately 25% of patients who receive primary prevention ICDs may no
longer meet guideline indications for ICD use at the time of generator replacement, and
further studies are required to understand the best subsequent action.
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Jong-Min Song, Seung Woo Park, Cheol-Hyun Chung, Jae-Kwan Song, Jae-Won Lee, Pyo-Won Park
This study sought to compare long-term outcomes of early surgery versus conventional
treatment strategy in asymptomatic patients with severe mitral regurgitation (MR). Of
610 consecutive asymptomatic patients with severe degenerative MR and preserved left
ventricular function, 235 patients underwent early surgery, and the remainder received
conventional treatment. For 238 propensity score–matched pairs, early surgery had a
signiﬁcantly lower risk of overall mortality (hazard ratio [HR]: 0.491), cardiac mortality
(HR: 0.094), and cardiac events (HR: 0.103) than conventional treatment. In asymptomatic
severe MR, these beneﬁts were particularly evident among patients age 50 years.
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Dylmitr Rittoo, Alan Jones, Bryan Lecky, Duncan Neithercut
This study sought to determine the clinical and biological signiﬁcance of elevated cardiac
troponin T (cTnT) in patients with neuromuscular disease. A total of 52 patients with
20 different types of acquired and inherited neuromuscular disease underwent full clinical
assessment and measurement of biomarkers. Serial measurements in 25 initially-hospitalized
patients over a mean of 2.4 years showed persistent elevation of cTnT (median 0.08 mg/l),
creatine kinase (CK) (median 582 U/l), and creatine kinase myocardial band (CK-MB)
(median 24 mg/l). Cardiac troponin I (cTnI) was persistently normal. Single measurements in
27 ambulatory patients showed elevated CK, CK-MB, and cTnT in the majority of patients.
CTnI was abnormal in only 1 patient. Patients with a wide spectrum of neuromuscular
disease commonly have persistent elevation of cTnT and CK-MB in the absence of clinical
and cTnI evidence of myocardial injury.(continued on page A-36)
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The objective of this study was to test 2 hypotheses: 1) ﬁbroblast growth factor (FGF)-23
identiﬁes patients with stable ischemic heart disease (SIHD) who are at high risk of
cardiovascular events independent of renal function, clinical factors, and established
cardiovascular biomarkers; and 2) FGF-23 identiﬁes patients who derive clinical beneﬁt
from angiotensin-converting enzyme (ACE) inhibitor therapy. FGF-23 levels were measured
in 3,627 SIHD patients randomized to trandolapril or placebo within the PEACE
(Prevention of Events with Angiotensin Converting Enzyme) trial; patients were followed
for a median of 5.2 years. After adjustment for risk factors, the top quartile of FGF-23
concentration was independently associated with an increased risk of cardiovascular death or
heart failure among patients allocated to placebo (hazard ratio [HR]: 1.73). Additionally,
among these patients, trandolapril signiﬁcantly reduced cardiovascular death or incident heart
failure (HR: 0.45). Elevated levels of FGF-23 are associated with cardiovascular death and
incident heart failure in SIHD patients and identify patients who derive signiﬁcant clinical
beneﬁt from ACE inhibitor therapy regardless of renal function.
